Anti-cancer drug characterisation using a human cell line panel representing defined types of drug resistance

被引:72
作者
Dhar, S
Nygren, P
Csoka, K
Botling, J
Nilsson, K
Larsson, R
机构
[1] UNIV UPPSALA HOSP,DIV CLIN PHARMACOL,S-75185 UPPSALA,SWEDEN
[2] UNIV UPPSALA HOSP,DEPT ONCOL,S-75185 UPPSALA,SWEDEN
[3] UNIV UPPSALA HOSP,DEPT PATHOL,S-75185 UPPSALA,SWEDEN
关键词
anti-cancer drug; human tumour cell line; cytotoxicity; drug resistance; screening;
D O I
10.1038/bjc.1996.453
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Differential drug response in a human cell line panel representing defined types of cytotoxic drug resistance was measured using the non-clonogenic fluorometric microculture cytotoxicity assay (FMCA). In total 37 drugs were analysed; eight topoisomerase II inhibitors, eight anti-metabolites, eight alkylating agents, eight tubulin-active agents and five compounds with other or unknown mechanisms of action, including one topoisomerase I inhibitor. Correlation analysis of log IC50 values obtained from the panel showed a high degree of similarity among the drugs with a similar mechanism of action. The mean percentage of mechanistically similar drugs included among the ten highest correlations, when each drug was compared with the remaining data set, was 100%, 92%, 88% and 52% for the topoisomerase II inhibitors, alkylators, tubulin-active agents and anti-metabolites respectively. Classification of drugs into the four categories representing different mechanisms of action using a probabilistic neural network (PNN) analysis resulted in 29 (91%) correct predictions. The results indicate the feasibility of using a limited number of cell lines for prediction of mechanism of action of anti-cancer drugs. The present approach may be well suited for initial classification and evaluation of novel anticancer drugs and as a potential tool to guide lead compound optimisation.
引用
收藏
页码:888 / 896
页数:9
相关论文
共 51 条
[1]  
ALLEY MC, 1988, CANCER RES, V48, P589
[2]   GENERATION OF A DRUG-RESISTANCE PROFILE BY QUANTITATION OF MDR-1/P-GLYCOPROTEIN IN THE CELL-LINES OF THE NATIONAL-CANCER-INSTITUTE ANTICANCER DRUG SCREEN [J].
ALVAREZ, M ;
PAULL, K ;
MONKS, A ;
HOSE, C ;
LEE, JS ;
WEINSTEIN, J ;
GREVER, M ;
BATES, S ;
FOJO, T .
JOURNAL OF CLINICAL INVESTIGATION, 1995, 95 (05) :2205-2214
[3]  
ANDERSON LA, 1990, ELECTROPHORESIS, V12, P907
[4]  
BAAS F, 1990, CANCER RES, V50, P5392
[5]   THE CELL BIOLOGY OF MULTIPLE-DRUG RESISTANCE [J].
BECK, WT .
BIOCHEMICAL PHARMACOLOGY, 1987, 36 (18) :2879-2887
[6]  
BECK WT, 1987, CANCER RES, V47, P544
[7]  
BELLAMY WT, 1991, CANCER RES, V51, P995
[8]   DEVELOPMENT OF VINCRISTINE RESISTANCE AND INCREASED SENSITIVITY TO CYCLOSPORINE-A AND VERAPAMIL IN THE HUMAN U-937 LYMPHOMA CELL-LINE WITHOUT OVEREXPRESSION OF THE 170-KDA P-GLYCOPROTEIN [J].
BOTLING, J ;
LIMINGA, G ;
LARSSON, R ;
NYGREN, P ;
NILSSON, K .
INTERNATIONAL JOURNAL OF CANCER, 1994, 58 (02) :269-274
[9]  
Boyd M. R., 1993, CURRENT THERAPY ONCO, P11
[10]   SOME PRACTICAL CONSIDERATIONS AND APPLICATIONS OF THE NATIONAL-CANCER-INSTITUTE IN-VITRO ANTICANCER DRUG DISCOVERY SCREEN [J].
BOYD, MR ;
PAULI, KD .
DRUG DEVELOPMENT RESEARCH, 1995, 34 (02) :91-109